Fasting Glucose in the High-Normal Range and Early Risk

A fasting glucose reading between 85 and 99 mg/dL can be within the normal lab range and still be an early clue to metabolic and cardiovascular risk. The useful response is neither alarm nor dismissal. It is to understand what the test can miss, place the result beside other markers, and use that fuller picture to guide low-risk changes before a diagnostic threshold is crossed.

Why a fasting glucose between 85 and 99 mg/dL is not simply "normal"

The lab report says “93 mg/dL — normal,” and the conversation ends there. For someone looking for reassurance, that seems clear enough. But what does “normal” actually establish? It tells the reader where the result falls within a diagnostic range, leaving open whether every process keeping glucose in that range is working well. Those are different questions with different answers.

The American Diabetes Association classifies fasting plasma glucose below 100 mg/dL as normal, 100–125 mg/dL as prediabetes, and 126 mg/dL or above as diabetes. These thresholds give clinicians a shared framework for identifying abnormal glucose levels. They do not mark the first moment that metabolic risk appears. A conventional fasting range of 70–99 mg/dL therefore serves a narrower purpose than many readers assume when they see an unflagged result.

The distinction is between classification and physiology. Insulin and glucagon regulate fasting glucose, but a result does not reveal how much compensatory work was needed to produce it. The stretch from roughly 85 to 99 mg/dL deserves attention because it can contain an early risk signal without triggering a warning on the report. That makes “normal” an incomplete answer to a question about long-term health.

What fasting glucose is actually measuring — and when it starts to change

Fasting glucose measures the balance between the glucose that enters the blood and the glucose that leaves it after an overnight fast. The liver supplies glucose by making it through gluconeogenesis and releasing it from stored glycogen through glycogenolysis. Tissues, which include skeletal muscle and the brain, take up glucose. Insulin helps suppress the liver’s output and promotes uptake, while glucagon stimulates release when glucose falls too low.

When cells become less responsive to insulin, the pancreas can compensate by producing more of it. Glucose may remain within the normal range because that extra insulin is doing enough to keep it there. Fasting insulin can therefore rise before fasting glucose does, concealing an underlying loss of insulin sensitivity.

This compensation can continue for years. A high-normal glucose reading cannot establish how long insulin resistance has been present, or establish by itself that insulin resistance is present at all. It shows the outcome of regulation.

Why, then, measure fasting glucose at all? Its relative stability makes a change useful, especially when results are considered over time. The limitation is that stability can reflect either healthy regulation or successful compensation. A reading that begins to climb may thus be a delayed signal of a process that started earlier.

How cardiovascular risk rises continuously within the normal glucose range

Population research asks a different question from a diagnostic guideline. It looks at how outcomes change with glucose levels rather than where to draw the line between categories. Cardiovascular risk can rise within a range even when the lab gives everyone in it the same label.

The Framingham Offspring Study and the ARIC study support a continuous association between fasting glucose and cardiovascular risk within the conventionally normal range, including above approximately 85 mg/dL. The risk gradient extends across the diagnostic boundary at 100 mg/dL. This means the upper part of the normal range should not be treated as a risk-free plateau.

Does that make a reading of 92 mg/dL a prediction of cardiovascular disease? The population association places that result on a different part of the observed gradient from a reading of 79 mg/dL, and quantifying a person’s overall cardiovascular risk requires more than glucose alone. The association also does not show that lowering a single reading will, on its own, prevent an event.

The practical significance is therefore broader than the number. High-normal glucose can point to metabolic conditions that also affect vascular health as well as to the chance of diabetes later on. That is why further assessment considers whether other evidence shows the body is already compensating and whether other cardiovascular risk markers are present.

Why fasting glucose alone cannot see what is already happening

A glucose-only screen cannot distinguish normal regulation from regulation maintained by unusually high insulin. Consider a fasting glucose of 88 mg/dL. That result can coexist with elevated fasting insulin and a HOMA-IR result suggesting substantial insulin resistance, even though glucose itself earns no flag. The missing information is the compensatory response.

Fasting insulin measures that response more directly. HOMA-IR combines fasting insulin and fasting glucose to estimate insulin resistance, giving the glucose result a context it lacks on its own. Yet fasting insulin is not routinely included in standard panels in the US or most of Europe. The marker that could reveal compensation may therefore be absent from an otherwise reassuring set of results.

Additional testing has limits of its own. Fasting insulin assays are not standardized, and cutoffs for interpreting insulin resistance remain debated. HOMA-IR is consequently not a self-diagnosis tool or a universal pass-or-fail score. These results belong in a discussion with a clinician who can interpret them with the rest of the clinical picture.

HbA1c shows average glucose over about 90 days, which can be compared with fasting glucose. A rising fasting glucose with a stable HbA1c can suggest worsening hepatic insulin resistance, because the fasting result reflects the liver’s overnight contribution more specifically than the average does. Combining markers can uncover relationships that one measurement cannot show.

The concept of pre-prediabetes and what it means for when to act

UT San Antonio Health Science Center research published in Diabetes Care in 2025 proposed a risk stage called “pre-prediabetes.” The researchers found people with normal glucose tolerance who already had severe insulin resistance, early beta-cell dysfunction, and cardiovascular disease that could be measured. The proposed stage draws attention to what happens before conventional prediabetes. It also challenges the assumption that a normal glucose result necessarily means the underlying process has not begun.

Insulin resistance and changes in the insulin-producing beta cells can precede an abnormal glucose signal. The researchers suggested considering oral glucose tolerance tests for more people, especially those in high-risk populations, to find problems that standard screening may miss.

A proposed stage is not a settled guideline. One study cannot establish a universal testing strategy or make everyone with normal glucose a patient in waiting. Its contribution is to strengthen the case for examining metabolic function before traditional thresholds are crossed. For a reader deciding when to pay attention, this supports discussing earlier assessment when risk is present.

The companion markers that complete the early-risk picture

Lipid patterns, particularly elevated ApoB and small, dense LDL, can occur with insulin resistance and compound cardiovascular risk. A standard cholesterol result may not show all of that pattern. The detection gap is not confined to glucose testing.

ApoB measures the number of atherogenic lipoprotein particles, a quantity distinct from the amount of cholesterol they contain. This distinction is especially useful in metabolic syndrome, insulin resistance, or dyslipidemia, where particle number and cholesterol mass can diverge. Someone can have conventionally normal LDL cholesterol and high ApoB. In those circumstances, ApoB can be more predictive of cardiovascular events than the cholesterol result alone.

hs-CRP gives information about systemic inflammation, which can occur alongside early glucose dysregulation and is itself linked to cardiovascular risk. It does not answer the same question as glucose or ApoB. Considering the three together gives a broader view of vascular risk than treating each unflagged result as separate reassurance.

For someone with high-normal fasting glucose, a practical panel to discuss with a clinician includes fasting glucose, fasting insulin, HbA1c, ApoB, and hs-CRP. Fasting insulin is needed to calculate HOMA-IR, while HbA1c shows what glucose has been like over a longer period. ApoB addresses particle number, and hs-CRP adds the inflammatory dimension.

This is not a mandate for indiscriminate testing. The panel structures an early-risk discussion for results below 100 mg/dL, where no diagnostic category is established. Its value depends on interpretation, including the limitations of insulin testing. A fuller picture should make decisions more proportionate, rather than make an otherwise healthy person anxious about every measurement.

What the research supports for bringing high-normal glucose down

The strongest case for acting early is that diet and physical activity can address the underlying process without requiring a disease diagnosis. These are low-risk, non-pharmaceutical approaches. Their purpose is to improve insulin sensitivity and long-term health while there is still an opportunity to change course.

The Diabetes Prevention Program established that a lifestyle intervention targeting a modest reduction in initial body weight and a meaningful increase in weekly physical activity substantially reduced diabetes incidence. The lifestyle group’s effect exceeded that of the metformin-treated group compared with placebo. That finding supports the value of behavioral change in prevention. It does not establish that every person with a fasting glucose of 85–99 mg/dL needs weight loss or would obtain the same benefit.

A randomized controlled trial also found significant improvements in fasting glucose in a combined exercise-and-diet group, but not in an exercise-only group. Within that trial, combining the two approaches made the difference. Dietary change should be considered together with physical activity rather than assuming exercise alone will address the whole problem. It would be too strong to conclude that exercise without dietary change never helps.

The ADA’s physical activity guidance supports regular moderate-to-vigorous-intensity aerobic exercise for glucose management and cardiovascular health. It also supports 2–3 resistance-training sessions weekly for body composition, lipid profiles, and cardiovascular health. This gives the reader a concrete direction without turning a high-normal result into a prescription for medication. The aim should be a pattern that can be kept up without fear over a single number.

There is a fair objection to this approach. No major guideline from the ADA, WHO, or USPSTF formally defines a risk category below 100 mg/dL, and labeling the high-normal range as disease would pathologize many people. But paying attention is not the same as diagnosing. The evidence supports looking at the result in context, discussing it with a clinician when needed, and making low-risk lifestyle changes, without assuming that treatment is needed or that danger starts at one exact value.

A high-normal fasting glucose result is best understood as a signal. The goal is not to fear a normal report, but to understand what it can (and cannot) say about the years ahead.